News | EP Lab | May 15, 2019

Implantable EP Device Infection Risk Score Unveiled at HRS 2019

Update from the prevention of arrhythmia device infection trial (PADIT)

A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 


May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

"We developed a novel infection risk score in the largest cardiovascular implantable electronic device (CIED) trial to date, with five independent predictors that are readily adopted into clinical practice," explained Andrew D.. Krahn, M.D., FHRS, professor in the Division of Cardiology at the University of British Columbia, who presented the study. He said the PADIT infection score warrants validation in an independent cohort study.

CIED infection is a major complication, usually requiring device removal. The Prevention of Arrhythmia Device Infection Trial (PADIT) was a large cluster crossover trial of standard versus incremental antibiotics. Krahn said the study sought to investigate independent predictors of device infection in PADIT and develop a novel infection risk score. Device procedures were performed in 19,603 patients and hospitalization for infection occurred in 177 (0.90%) within one year. 

Over four six-month periods, 24 centers used either conventional or incremental antibiotic treatment in all patients. The primary outcome was hospitalization for device infection within one year with blinded end-point adjudication. Multivariable logistic prediction modeling was used to identify the independent predictors and develop a risk score for device infection. The model was internally validated with bootstrap methods.

The final prediction model identified five independent predictors of device infection (previous procedures (N), age, decreased renal function, immuno-compromised, and type of procedure) with optimizm-corrected C-statistic of 0.704 (95% CI, 0.660-0.744).

 

The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups:

   • Low (0-4)

   • Intermediate (5-6)

   • High (≥7)

 

The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively (also see figure 1). Subgroup analysis by PADIT infection risk score of the two antibiotic regimes showed no treatment effect (pinteraction = 0.37).

 

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

 

Reference: 

1. Krahn AD, Longtin Y, Philippon F, et al. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. J Am Coll Cardiol. 2018 Dec 18;72(24):3098-3109. doi: 10.1016/j.jacc.2018.09.068.


Related Content

News | EP Lab

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its ...

Home January 29, 2026
Home
News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
Subscribe Now